CXCR2-IN-1

Research use only, not for human use.

A potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6.

A potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6; has developability profiles (CYP inhibition pIC<5.0, and hERG binding affinity pIC<4.0); exhibits favorable PK profile, reasonable CNS penetration, and good developability potential; orally bioavailable.

CXCR2 plays an important role in the activation and recruitment of neutrophils to sites of inflammation. CXCR2-IN-1 (compound 22) shows favorable central nervous system penetration property (Br/Bl>0.45).

CXCR2-IN-1 shows efficacy in a cuprizone-induced demyelination model through oral administration, providing evidence to support CXCR2 to be a potential therapeutic target to treat demyelinating diseases such as multiple sclerosis.

——

GPCR/G Protein

Chemokine Receptor

Chemokine Receptor

——

——

1873376-49-8

476.3492032

C19H20Cl2FN3O4S

>98% (HPLC)

DMSO: ≥5.4 mg/mL (Need ultrasonic and warming)

CN1CCC(CC1)S(=O)(=O)C2=C(C=CC(=C2O)NC(=O)NC3=C(C(=CC=C3)F)Cl)Cl

Urea, N-(2-chloro-3-fluorophenyl)-N'-[4-chloro-2-hydroxy-3-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-

(-20℃)

With Ice Pack

≥ 2 years